{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:04:25Z","timestamp":1790697865448,"version":"4.1.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To characterize retina specialists\u2019 perceptions of the intravitreal (IVT) bevacizumab supply chain after the manufacturer, Pine Pharmaceuticals, announced they would no longer produce the formulation.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A 22-question survey was created to assess retina physicians\u2019 use of IVT bevacizumab, perceptions of the supply chain, and how the decision will affect patient care. The survey was electronically distributed to all members of the American Society of Retina Specialists.\n                    <jats:bold>Results:<\/jats:bold>\n                    The survey was completed by 287 retina specialists. In the 3 months before the survey, 194 (67.6%) physicians reported receiving IVT bevacizumab from Pine Pharmaceuticals. Approximately 85% of physicians were either very concerned (158 [55.4%]) or concerned (85 [29.8%]) about their access to the medication in the next 3 months. Most physicians anticipated needing to delay or change patient appointments (142 [50.4%]) or change patient treatment plans (179 [63.9%]) because of shortages of IVT bevacizumab. Respondents overwhelmingly believed that patients with step-therapy requirements were most likely to be affected by appointment delays (119 [83.8%]) and changes in treatment plans (140 [78.2%]).\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    The majority of retina specialists surveyed expect the decision to halt production of IVT bevacizumab will significantly disrupt access to the medication and adversely affect patient care. Most physicians predict delays and changes in treatment, particularly for patients with IVT bevacizumab step-therapy requirements. Therefore, to minimize negative effects on patient care, we recommend that carriers suspend step-therapy requirements, especially given that the disruption to the supply chain is likely to be longstanding.\n                  <\/jats:p>","DOI":"10.1177\/24741264251352889","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T14:57:22Z","timestamp":1752073042000},"page":"550-554","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Supply Chain Volatility of Repackaged Intravitreal Bevacizumab: A Survey of the American Society of Retina Specialists"],"prefix":"10.1177","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6114-0996","authenticated-orcid":false,"given":"Hasenin","family":"Al-khersan","sequence":"first","affiliation":[{"name":"Retina Consultants of Texas, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-8486","authenticated-orcid":false,"given":"Miguel","family":"Busquets","sequence":"additional","affiliation":[{"name":"Retina Associates of Kentucky, EyeCare Partners, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Ghorayeb","sequence":"additional","affiliation":[{"name":"West Virginia University, Morgantown, WV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2055-9453","authenticated-orcid":false,"given":"Dan","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Kolomeyer","sequence":"additional","affiliation":[{"name":"NJRetina, Teaneck, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella H.","family":"Leung","sequence":"additional","affiliation":[{"name":"Georgia Retina, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Niles","sequence":"additional","affiliation":[{"name":"Buffalo Niagara Retina Associates, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimesh A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankoor R.","family":"Shah","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Blim","sequence":"additional","affiliation":[{"name":"American Society of Retina Specialists, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Jumper","sequence":"additional","affiliation":[{"name":"American Society of Retina Specialists, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Lai","sequence":"additional","affiliation":[{"name":"Retina Group of Washington, Chevy Chase, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3928\/1542-8877-20050701-14"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414264"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2009.02.004"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.041"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-016-0391-4"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2009.219"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.08.021"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.11.035"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2101.141040"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.3591"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.1815"},{"key":"e_1_3_3_14_2","unstructured":"American Academy of Ophthalmology. Pine Pharmaceuticals Discontinues Avastin and Other Ophthalmic Product Manufacturing. 2024. Accessed November 21 2024. https:\/\/www.aao.org\/advocacy\/eye-on-advocacy-article\/pine-pharmaceuticals-avastin-ophthalmic-product"},{"key":"e_1_3_3_15_2","unstructured":"TipRanks. Outlook could disrupt ocular anti-VEGF injection market says BTIG. 2024. Accessed November 21 2024. https:\/\/www.tipranks.com\/news\/the-fly\/outlook-could-disrupt-ocular-anti-vegf-injection-market-says-btig#google_vignette"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0313298"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2023.89426"},{"key":"e_1_3_3_18_2","unstructured":"American Academy of Ophthalmology. Academy urges insurers to suspend step therapy due to potential avastin supply issues. 2024. Accessed November 20 2024. https:\/\/www.aao.org\/advocacy\/eye-on-advocacy-article\/insurers-urged-suspend-step-therapy-due-avastin#:~:text=Academy%20Urges%20Insurers%20to%20Suspend%20Step%20Therapy%20Due%20to%20Potential%20Avastin%20Supply%20Issues -Add%20to%20My&text=The%20Academy%20urged%20large%20commercial of%20repackaged%20Avastin%20(bevacizumab)"},{"key":"e_1_3_3_19_2","unstructured":"American Society of Retina Specialists. ASRS AAO Call on CMS to suspend Avastin-first step therapy policies; Caremark\/Aetna requests shortage notation on authorization forms. 2024. Accessed November 15 2024. https:\/\/www.asrs.org\/advocacy\/updates\/10392\/asrs-aao-call-on-cms-to-suspend-avastin-first-step-therapy-policies-caremark-aetna-requests-shortage#:~:text=This%20morning%2C%20ASRS%20and%20AAO is%20ceasing%20repackaging%20of%20Avastin"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2117582"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/2474126417738627"},{"issue":"7","key":"e_1_3_3_22_2","first-page":"1072","article-title":"One-year outcome of intravitreal bevacizumab on eyes with choroidal neovascularization secondary to central serous chorioretinopathy","volume":"61","author":"Hagag AM","year":"2020","unstructured":"Hagag AM, Chandra S, Khalid H, Lamin A, Keane PA, Sivaprasad S. One-year outcome of intravitreal bevacizumab on eyes with choroidal neovascularization secondary to central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2020;61(7):1072-1072.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.11.045"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251352889","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264251352889","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251352889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:24:30Z","timestamp":1790695470000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264251352889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1177\/24741264251352889"],"URL":"https:\/\/doi.org\/10.1177\/24741264251352889","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}